Answers are grounded in this paper and cite their sources.
Polyendocrine Metabolic Ovarian Syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), is a common endocrine disorder in women of reproductive age. The prevalence of PMOS among female athletes remains uncertain because of inconsistent findings across studies. This systematic review and meta-analysis aimed to estimate the pooled prevalence of PMOS among young female athletes and to examine how the diagnostic definition, case ascertainment and study selection affect the estimate. PubMed and Embase were searched from inception to June 2026 for observational studies reporting the prevalence of PMOS (formerly PCOS) in young female athletes. PMOS had to be established by syndrome-level criteria (Rotterdam, NIH or AE-PCOS) or a clinician diagnosis; studies reporting only polycystic ovarian morphology or an androgen index were not pooled, and overlapping cohorts were counted once. A single-arm meta-analysis of proportions used a random-intercept generalized linear mixed model with logit transformation and 95% prediction intervals. Subgroup analysis by diagnostic method and sensitivity analyses (leave-one-out, exclusion of a clinic-based adolescent sample, exclusion of studies at high risk of bias, and alternative denominators) were performed. Risk of bias was assessed with the Joanna Briggs Institute checklist for prevalence studies. The protocol was prospectively registered in PROSPERO (CRD420261448678); the sensitivity analyses added during peer review were post hoc. Eight studies (2,544 athletes) were identified. Five independent cohorts (1,254 athletes) established PMOS by syndrome-level criteria and entered the primary analysis; a second report of one Iranian cohort was excluded as overlapping, and two studies that measured only polycystic ovarian morphology or an elevated free androgen index were not pooled. The pooled prevalence was 5.7% (95% CI 1.8% to 16.6%), with a 95% prediction interval of 0.1% to 76.0% and I² = 92.5%. Pooled estimates ranged from 2.7% to 10.6% across sensitivity analyses and was 3.1% (95% CI 1.7% to 5.7%) after omission of a clinic-based adolescent study ( n = 18). Prevalence was 7.9% (1.3% to 36.4%) in studies using the Rotterdam criteria and 3.9% (2.3% to 6.5%) in studies using self-reported physician diagnosis; the test for subgroup differences was not significant ( P = 0.46) but had little power with five studies. Heterogeneity was substantial and the pooled value should not be read as a stable estimate. The prevalence of PMOS in female athletes cannot be estimated precisely from the available evidence. The pooled estimate of about 6% is compatible with true values from below 2% to above 15%, and it varied with the diagnostic method, the denominator and the inclusion of single small studies. Studies that apply standardized syndrome-level criteria to all athletes in representative samples are needed. The pooled estimate is not a precise population-level prevalence and should not be taken to establish the prevalence of PMOS in all female athletes. Not applicable.
No takes yet. Share an insight, caveat, or question.
Shahine et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: